Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its anti-PD-1 monoclonal antibody to Incyte for $795 million; Ascletis Pharma of Hangzhou raised $35 million in a funding led by C-Bridge Capital; iKang Healthcare is considering a $1.1 billion go-private offer from a group led by its Founder/Chairman/CEO; Celyad, a Belgium cell therapy company, announced an altered China collaboration with Medisun for a stem cell heart failure treatment; Hutchison MediPharma reported that fruquintinib met its primary endpoint in a Phase II China trial for non-small cell lung cancer; Ascletis Pharma of Hangzhou was approved to begin a Phase II trial in Taiwan of its dual-drug, interferon-free treatment for chronic hepatitis C; MicuRx Pharma, a US-China antibiotics company, announced positive data from a China Phase II clinical trial of its novel antibiotic; the CFDA is seeking to recruit an additional 69 people to review drug approval submissions; and China drugmakers have begun hiring experienced Indian pharma execs, offering them two to three times their present salaries, to develop generics for western markets.
Help employers find you! Check out all the jobs and post your resume.
